Krystal Biotech, Inc. announced that the last participant has completed the GEM-3 study, Krystal’s pivotal Phase III clinical trial evaluating investigational beremagene geperpavec (B-VEC) as a topical gene therapy for the treatment of dystrophic epidermolysis bullosa.
[Krystal Biotech, Inc.]
7992332
{7992332:nan}
apa
50
1
168426
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/